دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Cerebral Amyloid Angiopathy—How to Translate Updated Diagnostic Criteria for This Multifaceted Disorder to Clinical Practice?
Geert Jan Biessels, PhD1; Ana Sofia Costa2,3
doi : 10.1001/jamaneurol.2022.5060
March 2023, Vol 80, No. 3, Pages 224-324
Challenges and Opportunities for Clinical Trials in Patients With Glioma
L. Nicolas Gonzalez Castro, MD, PhD1,2; Isabel C. Arrillaga-Romany, MD, PhD3; Tracy T. Batchelor, MD4,5
Building Evidence on Safety of Thrombolysis for Patients Undergoing Direct Oral Anticoagulant Treatment
Eva A. Mistry, MBBS, MSCI1
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
Thomas R. Meinel, MD1; Duncan Wilson, PhD2,3; Henrik Gensicke, MD4,5; Jan F. Scheitz, MD6,7,8; Peter Ringleb, MD9; Ioana Goganau, MD9; Johannes Kaesmacher, MD10; Hee-Joon Bae, MD11; Do Yeon Kim, MD11; Pawel Kermer, MD12,13; Kentaro Suzuki, MD14; Kazumi Kimura, MD14; Kosmas Macha, MD15; Masatoshi Koga, MD16; Shinichi Wada, MD16; Valerian Altersberger, MD4; Alexander Salerno, MD17; Logesh Palanikumar, MD18; Andrea Zini, MD19; Stefano Forlivesi, MD19; Lars Kellert, MD20; Johannes Wischmann, MD20; Espen S. Kristoffersen, MD, PhD21,22; James Beharry, MD23; P. Alan Barber, PhD24; Jae Beom Hong, MD24; Carlo Cereda, MD25; Eckhard Schlemm, MBBS, PhD26; Yusuke Yakushiji, MD27; Sven Poli, MD, MSc28,29; Ronen Leker, MD30; Michele Romoli, MD31; Marialuisa Zedde, MD32; Sami Curtze, MD33; Benno Ikenberg, MD34; Timo Uphaus, MD35; David Giannandrea, MD36; Pere Cardona Portela, MD37; Roland Veltkamp, MD9,38,39; Annemarei Ranta, PhD40,41; Marcel Arnold, MD1; Urs Fischer, MD1,4; Jae-Kwan Cha, MD42; Teddy Y. Wu, PhD2,3; Jan C. Purrucker, MD, MSc9; David J. Seiffge, MD1; and the International DOAC-IVT, TRISP, and CRCS-K-NIH Collaboration; and the DOAC-IVT Writing Group
doi : 10.1001/jamaneurol.2022.4782
Importance International guidelines recommend avoiding intravenous thrombolysis (IVT) in patients with ischemic stroke who have a recent intake of a direct oral anticoagulant (DOAC).
Effect of Self-treatment of Recurrent Benign Paroxysmal Positional VertigoA Randomized Clinical Trial
Hyo-Jung Kim, PhD1; Ji-Soo Kim, MD, PhD2,3; Kwang-Dong Choi, MD, PhD4; Seo-Young Choi, MD, PhD4; Seung-Han Lee, MD, PhD5; Ileok Jung, MD2,6; Jae Han Park, MD7
doi : 10.1001/jamaneurol.2022.4944
Importance Benign paroxysmal positional vertigo (BPPV) is the most common cause of vertigo with frequent recurrences.
Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional OutcomesA Randomized Clinical Trial
Jacqueline J. Bosch, PhD1,2; Martin J. O’Donnell, MD3; Peggy Gao, MSc1; Philip Joseph, MD1; Prem Pais, MD4; Denis Xavier, MD4; Antonio Dans, MD5; Patricio Lopez Jaramillo, MD6; Salim Yusuf, DPhil1
doi : 10.1001/jamaneurol.2022.5088
Importance Vascular risk factors are associated with cognitive decline but studies addressing individual risk factors have not demonstrated an effect of risk factor management on the preservation of cognition. Few trials have examined the effect of vascular risk factor management on function.
Head Injury and Long-term Mortality Risk in Community-Dwelling Adults
Holly Elser, MD, PhD1; Rebecca F. Gottesman, MD, PhD2; Alexa E. Walter, PhD1; Josef Coresh, MD, PhD3; Ramon Diaz-Arrastia, MD, PhD1; Thomas H. Mosley, PhD4; Andrea L. C. Schneider, MD, PhD1,5
doi : 10.1001/jamaneurol.2022.5024
Importance Head injury is associated with significant short-term morbidity and mortality. Research regarding the implications of head injury for long-term survival in community-dwelling adults remains limited.
Assessment of Safety of a Fully Implanted Endovascular Brain-Computer Interface for Severe Paralysis in 4 PatientsThe Stentrode With Thought-Controlled Digital Switch (SWITCH) Study
Peter Mitchell, MMed1; Sarah C. M. Lee, MBBS2; Peter E. Yoo, PhD3; Andrew Morokoff, MD4; Rahul P. Sharma, MBBS5; Daryl L. Williams, MBBS6; Christopher MacIsaac, PhD7; Mark E. Howard, MBBS, PhD8; Lou Irving, MBBS9; Ivan Vrljic, BApSci1; Cameron Williams, MBBS10; Steven Bush, MBBS10; Anna H. Balabanski, MBBS10,11,12; Katharine J. Drummond, MD13; Patricia Desmond, MD1; Douglas Weber, PhD14; Timothy Denison, PhD15; Susan Mathers, MD2; Terence J. O’Brien, MD10,16,17; J. Mocco, MD18; David B. Grayden, PhD19; David S. Liebeskind, MD20; Nicholas L. Opie, PhD21,22; Thomas J. Oxley, MD, PhD3,21; Bruce C. V. Campbell, MD10,11
doi : 10.1001/jamaneurol.2022.4847
Importance Brain-computer interface (BCI) implants have previously required craniotomy to deliver penetrating or surface electrodes to the brain. Whether a minimally invasive endovascular technique to deliver recording electrodes through the jugular vein to superior sagittal sinus is safe and feasible is unknown.
Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries
Giancarlo Logroscino, MD1; Marco Piccininni, PhD2,3; Caroline Graff, MD4,5; Orla Hardiman, MD6,7; Albert C. Ludolph, MD8,9; Fermin Moreno, MD10,11; Markus Otto, MD8,12; Anne M. Remes, MD13,14,15; James B. Rowe, MD16; Harro Seelaar, MD17; Eino Solje, MD, PhD18,19; Elka Stefanova, MD20; Latchezar Traykov, MD21; Vesna Jelic, MD22,23; Melissa Taheri Rydell, MD4; Niall Pender, PhD6,7; Sarah Anderl-Straub, MD8; Myriam Barandiaran, MD10,11; Alazne Gabilondo, MD10,11; Johanna Krüger, MD13,14,24; Alexander G. Murley, MD16; Timothy Rittman, MD16; Emma L. van der Ende, MD17; John C. van Swieten, MD17; Päivi Hartikainen, MD19; Gorana Mandić Stojmenović, MD20; Shima Mehrabian, MD21; Luisa Benussi, PhD25; Antonella Alberici, MD26; Maria Teresa Dell’Abate, PhD1; Chiara Zecca, PhD1; Barbara Borroni, MD26; for the FRONTIERS group
doi : 10.1001/jamaneurol.2022.5128
Importance Diagnostic incidence data for syndromes associated with frontotemporal lobar degeneration (FTLD) in multinational studies are urgent in light of upcoming therapeutic approaches.
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis
Stephanie Meier, MSc1,2,3; Eline A.J. Willemse, PhD1,2,3,4; Sabine Schaedelin, MSc1,2,3,4; Johanna Oechtering, MD1,2,3; Johannes Lorscheider, MD1,2,3; Lester Melie-Garcia, PhD1,2,3,5; Alessandro Cagol, MD1,2,3,5; Muhamed Barakovic, PhD1,2,3,5; Riccardo Galbusera, MD1,2,3,5; Suvitha Subramaniam, MSc1,2,3,4; Christian Barro, MD6; Ahmed Abdelhak, MD7; Simon Thebault, MD8; Lutz Achtnichts, MD9; Patrice Lalive, MD10; Stefanie Müller, MD11; Caroline Pot, MD12; Anke Salmen, MD13; Giulio Disanto, MD14,15; Chiara Zecca, MD14,15; Marcus D’Souza, MD1,2,3; Annette Orleth, PhD1,2,3; Michael Khalil, MD16; Arabella Buchmann, MSc16; Renaud Du Pasquier, MD17; Özgür Yaldizli, MD1,2,3,5; Tobias Derfuss, MD1,2,3; Klaus Berger, MD18; Marco Hermesdorf, MD18; Heinz Wiendl, MD19; Fredrik Piehl, MD20,21; Marco Battaglini, PhD22; Urs Fischer, MD1,2,3; Ludwig Kappos, MD1,2,3; Claudio Gobbi, MD14,15; Cristina Granziera, MD1,2,3,5; Claire Bridel, MD10; David Leppert, MD1,2,3; Aleksandra Maleska Maceski, MSc1,2,3; Pascal Benkert, PhD1,2,3,4; Jens Kuhle, MD1,2,3
doi : 10.1001/jamaneurol.2022.5250
Importance There is a lack of validated biomarkers for disability progression independent of relapse activity (PIRA) in multiple sclerosis (MS).
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple SclerosisThe Antelope Phase 3 Randomized Clinical Trial
Bernhard Hemmer, MD1; Heinz Wiendl, MD2; Karsten Roth, PhD3; Hendrik Wessels, PhD3; Josef Höfler, PhD4; Cyrill Hornuss, MD5; Bernd Liedert, PhD5; Krzysztof Selmaj, MD, PhD6
doi : 10.1001/jamaneurol.2022.5007
Importance Proposed biosimilar natalizumab (biosim-NTZ) PB006 is the first biosimilar monoclonal antibody therapy developed for multiple sclerosis (MS) treatment.
Management of Trigeminal Autonomic Cephalalgias Including Chronic ClusterA Review
Hans Christoph Diener, MD1; Cristina Tassorelli, MD2,3; David W. Dodick, MD4,5
doi : 10.1001/jamaneurol.2022.4804
Importance Trigeminal autonomic cephalalgias (TACs) comprise a unique collection of primary headache disorders characterized by moderate or severe unilateral pain, localized in in the area of distribution of the first branch of the trigeminal nerve, accompanied by cranial autonomic symptoms and signs.
Tic Status in Tourette Syndrome Due to Depletion of the Deep Brain Stimulation Battery
Jacy Bezerra Parmera, MD, PhD1; Joyce Yuri Silvestre Yamamoto, MD1; Rubens Gisbert Cury, MD, PhD1
Triple Benign Paroxysmal Positional Vertigo and the Strength of Remote Video-Based Management
Michael Strupp, MD1; Vergil Mavrodiev1; Nicolina Goldschagg, MD1
Severe Cervicodynia in a Patient With Pustules on the Palms
Cheng Xia, MD1; Yan Lv, MD1
